ImetelChat

I am going to suggest to you that they have. A close look at slide 28 from the January presentation tells the story. Look at 2022. The investment line for commercialization in Europe takes a turn straight up yet "approval" waits for 2024 in LR MDS. This suggests to me that this is the likely timelin...

Hi Ryan, I like your prognostication. Under promise: enrollment by end of second quarter. Overdeliver: April 13. Considering 100 active sites need deliver 85 more enrollees and we are there. This might move top line date forward. Regards, bp

2 MDS type side effects reported under investigation in Sickle Cell disease treatment. I am saddened to see a potential setback in the treatment of this terrible disease. https://www.marketwatch.com/story/bluebird-bio-shares-slide-34-after-company-suspends-trials-of-sickle-cell-disease-treatment-202...

Continued: 8. Are there any other drugs in the clinic that have shown disease modification and if so how does Imetelstat stack up against them? Where do you see the greatest competitive threats? Constellation Pharma has a BET inhibitor that is being studied in MF and that they believe has disease mo...

Gwickley, here is an example of the letter I wrote to Geron IR before the last shareholders meeting, with their responses. I posted this after I received it last year. The shareholders meeting really is a reasonable place to try to get information and potentially air grievances. At this point, given...

Rccola, Thanks for getting this clarified. Sounds like no MA until top line data. A shame really when a conditional approval could be granted on the basis of the conditions fulfilled as noted previously.

2.1.11. Imetelstat - Orphan - EMEA-001910-PIP03-20 Geron Corporation; Treatment of Acute Myeloid Leukemia (AML), Treatment of Myelodysplastic Syndromes (MDS), including Juvenile Myelomonocytic Leukemia (JMML) / Treatment of pediatric patients with relapsed or refractory AML or MDS, including JMML, f...

Gwickley, Pretty sure I have posted return letters here that I have received from Geron IR in response to my questions in the past. They have taken pains to respond and even followed up with clarifications after the last investor's meeting. I think it is worthwhile for you to compose a letter to the...

Pre COVID one could go to a shareholders meeting in May and ask in person. Some like Bridge did go and was quite satisfied with the reception and openness with which he was met. Nonetheless you can still submit questions for the shareholders meeting. In the past every question I have submitted was a...

Greetings to all. A couple of recent thoughts. It's still unclear as to why there was no update at ASH re the MDS P II study. While there were of course no new patients added since the last EHA presentation, I was as I am sure you were curious to know what the status of the remaining patients in stu...

The question before the house is whether Geron has any IP in the 6-THIO-dg arena.

To those trying to join the board, as I have noted previously (but those posts are probably buried), this board has been attacked by many bots (tens of thousands--I kid you not). If you are a potential legit poster please let me know on Geron YMB and I will sort through the bots posts and find you t...

From the EU re MA: "the benefit-risk balance of the medicine is positive". Check, just ask the KOLs "it is likely that the applicant will be able to provide comprehensive data post-authorisation"--two PIIIs in progress, Check "the medicine fulfils an unmet medical need"--huge transfusion requirement...

That's a good question. Here is what is a little incongruent. 1. Geron's strongest data presentations have been at European conferences. 2. Geron's strongest voices have been predominated by European physicians (with the exclusion of Dr. Mascarenhas and Dr. Steensma from the US). 3. Orphan designati...

https://journals.sagepub.com/doi/full/1 ... 0720986641


Only one agent reviewed here appears to be associated with disease modification. To clarify, disease modification=improved longevity, symptom control/regression etc.

Bill, not sure you are right about that, relevant proteins must be expressed as surface antigens. We have seen from these and previous article they do not appears to be. Thoughts?

Our Geron appears to be sailing successfully between the Scylla of FDA/EU/rest of the world regulation, and the Charybdis of competition (that would be a new drug class with no intraclass competition and new clearly defined treatment areas.). Thank you John and team. bp

Thanks Bill, so far I see work on melanoma, lymphoma and solid tumors. Did I miss something in reference to MDS/MF? If so please elaborate. Also maybe speculate on a reasonable timeline. Thanks, bp